and call. quarter everyone, market significant growing our Thank leadership underscores share quarter, some innovation, securing Good welcome We're stability. from to commitment long-term you, earnings this past our our and milestones which afternoon, third excited advancing to to Laura. financial
pleased our site at enrollments on external expectations. Gram-Negative on our X external update with an WAVE far. meets for trial's thus clinical track The testing expectations menu report laboratories and clinical to WAVE, meeting with system the all trial is Beginning we're performance that our
here review laboratorians a WAVE timeline demonstrating the of timely, the of our accurate to by systems improve enabling workflow. X in In reinforces addition, patient We submitting belief to with significantly diagnostics. ease strong approximately like The reliability, are of and the anticipate and WAVE's QX progress outcomes promising use FDA XXXX potential months. in
automated step reducing System the MALDI our obtaining blood clearance brings use with CA settings. including Bruker's Accelerate diagnostic in system, this us platform achievement was for quarter for major XXX(k) clinical times to a designed Another culture turnaround closer kit. This Biotyper Arc FDA
our is testing, rapid identification like mission with microbial supports for This, sepsis. to enhance workflow information future which along faster, by WAVE clinicians susceptibility accelerating critical cultures streamlined means positive decisions. from vital system's therapy Arc for antimicrobial stewardship especially can receive blood diagnostic The conditions our appropriate
commercial our to progress. turning Now
strides We beyond in focuses in positive reach market, core the broadening and markets. which our U.S. also our EMEA leadership landscape AST blood and our disrupting pillars: testing culture the executing isolate strategy, rapid commercial susceptibility X made on strengthening
to the U.S. extensions quarter, identification has significant been During rapid workflows. WAVE, we the a WAVE customer and contract commercial AST resulting of of point in discussions a launch. contracts customer with continued around committed Throughout sign anticipated customers, number focal through on centered conversations
test lab Pheno or which into actionable be while reminder, are WAVE, syndromic identification open PBC identification to PBC to opportunity a rapid method a molecular today samples. an of any X utilize categories: As PBC systems customers with conversion two, is for for wide WAVE WAVE. integrated one, and AST creating MALDI primarily fall range By their identification, is current we identification our to designed PBC to by our adoption the an uses assisting moving for identification; labs identification. market current Labs
MALDI the and by method, as PBC said, been inconsistent of can the for forward moved ID mainly the and adopting workflows create using lab are a low a of results MALDI with varying For the technicians has the ease laboratory these between we PBC cost MALDI for using drawback for the ID which market samples. using labs overnight adopted includes is discussed lab. the use, PBC already and advantages in is MALDI, once menu, major broader That rapid unless is system segment process past, manual preparing that a it
now clearance the PBC system compared samples rapidly price at into as opportunity to syndromic their preparation are Arc view options. about now to WAVE. provide rapidly by rapid we to a prepare PBC with cost-effective have when MALDI fortuitous, XXX(k) to of looking the integrating labs results excited automated WAVE. with sample the workflow given point convert molecular approval existing have Arc the a a automated great for We ID recent labs Customers With ID opportunity to for for and Arc, to fully cost-effective timing produce
platforms, The the ID rapid market, syndromic PBC other portion of to another WAVE AST. pair molecular large opportunity is with
used decision. lab rapid bring on on customers a site, a already WAVE PBC low has validated value have lift rapid running complement ID workflow. have other their syndromic Some and molecular for ID already Regardless, platform the which or testing see to to their is in
further on is the The centered which of from commercial part emerging market, isolate WAVE susceptibility our differentiates second strategy competitors.
menu As we which for with single our volumes platform, rather testing than labs a dialogue forcing will multiple lab specimens. consolidate unified confirms WAVE, develop demand AST utilize platforms a for to ongoing future customers for on the the various platform
platforms is market platform WAVE isolate a a market approximately testing on a given demand market As innovation, The for ripe susceptibility positioned AST meet the this by legacy today. delivering is reminder, and complete billion the aging is to solution. $X
for In WAVE samples, addition customers consolidation, same-shift delivers. AST desire to all platform reporting which
our the solutions and diagnostic and WAVE to other secondly, be provide fields. new technology of applications And we goal impactful to will thirdly, explore globally. markets diagnostic our imaging proprietary in in future, looking innovative bring These efforts holographic to further
as both growing by the encouraged including among progress summary, efforts, to trial in WAVE Arc our interest of clinical existing market date launch and new In commercial as in customers. and are well our we the highly the
this to reinforce this the achievements market strategic building progress and quarter We're the momentum coming commitment leadership. to our in Our in look energized by and priorities innovation quarters. on underscore our and forward
you it our QX. take Patience, to our David? will David over I'd hand financial to through who for performance CFO, Now like
